ERBB2 and breast carcinoma: These studies suggest a potential role for FASN in apoptosis, cell proliferation and invasion in HER2-overexpressing breast cancer cells and indicate the possibility that agents targeting FASN could be useful for treating breast cancers, especially those in which HER2 is overexpressed.